Sacituzumab Govitecan plus Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

被引：0

作者：

Patel, Jyoti ^{[1
]}

Cho, Byoung Chul ^{[2
]}

Dols, Manuel Cobo ^{[3
]}

Cabanillas, Roxanna Reyes ^{[4
]}

Baz, David Vicente ^{[5
]}

Pradera, Jose Fuentes ^{[6
]}

Grisanti, Salvatore ^{[7
]}

Gabayan, Afshin E. ^{[8
]}

Lee, Ki Hyeong ^{[9
]}

Cho, Eun Kyung ^{[10
]}

Mekan, Sabeen Fatima ^{[11
]}

Safavi, Farnoush ^{[11
]}

Fernando, Nalumka ^{[11
]}

Chisamore, Michael J. ^{[12
]}

Recki, Martin ^{[13
]}

机构：

[1] Robert H Lurie Comprehens Canc Ctr, Northwestern Med, Chicago, IL USA

[2] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[3] Reg & Virgen Victoria Univ Hosp, IBIMA, Malaga, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Hosp Univ Virgen Macarena, Seville, Spain

[6] Hosp Univ Virgen Valme, Seville, Spain

[7] ASST Spedali Civili Brescia, Brescia, Italy

[8] Beverly Hills Canc Ctr, Beverly Hills, CA USA

[9] Chungbuk Natl Univ Hosp, Cheongju, Chungbuk, South Korea

[10] Gachon Univ, Gil Med Ctr, Incheon, South Korea

[11] Gilead Sci Inc, Foster City, CA USA

[12] Merck & Co Inc, Rahway, NJ USA

[13] German Ctr Lung Res DZL, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PPD01.06

引用

页码：E6 / E7

页数：2

共 50 条

[31] Metastatic non-small cell lung cancer: A case study
Sherry, Victoria
NURSE PRACTITIONER, 2016, 41 (12): : 1 - 5
[32] TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
Zhou, C.
Levy, B. P.
Sands, J.
Parakh, S.
Sugawara, S.
Syrigos, K.
Ahn, J. S.
Zhao, M.
Lin, C. -C.
Felip, E.
Cappuzzo, F.
Reck, M.
Yang, J. C. H.
Joseph, R.
Rawat, S.
Xie, J.
Okamoto, I.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S327 - S328
[33] Linifanib Plus Carboplatin/Paclitaxel (CP) in Japanese Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) - Phase 1 Preliminary Results
Ohyanagi, F.
Horai, T.
Nishio, M.
Sekine, I.
Yamamoto, N.
Nakagawa, K.
Okamoto, I.
Terashima, M.
Li, X.
Tamura, T.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S629 - S629
[34] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
Schuler, Martin
Ramalingam, Suresh S.
Shi, Lei
Neibauer, Melissa Whipple
Frenkl, Tara
Stojadinovic, Alexander
Peters, Solange
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
[35] Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Paz-Ares, Luis G.
Juan-Vidal, Oscar
Mountzios, Giannis Socrates
Felip, Enriqueta
Reinmuth, Niels
de Marinis, Filippo
Girard, Nicolas
Patel, Vipul M.
Takahama, Takayuki
Owen, Scott Peter
Reznick, Douglas
Badin, Firas Benyamine
Cicin, Irfan
Mekan, Sabeen Fatima
Patel, Riddhi
Zhang, Eric
Karumanchi, Divyadeep
Garassino, Marina Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8500 - LBA8500
[36] Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
Fujimoto, Daichi
Miura, Satoru
Tomii, Keisuke
Sumikawa, Hiromitsu
Yoshimura, Kenichi
Wakuda, Kazushige
Oya, Yuko
Yokoyama, Toshihide
Kijima, Takashi
Asao, Tetsuhiko
Tamiya, Motohiro
Nakamura, Atsushi
Yoshioka, Hiroshige
Tokito, Takaaki
Murakami, Shuji
Tamiya, Akihiro
Yokouchi, Hiroshi
Watanabe, Satoshi
Yamaguchi, Ou
Morinaga, Ryotaro
Jodai, Takayuki
Ito, Kentaro
Shiraishi, Yoshimasa
Kogure, Yoshihito
Shibaki, Ryota
Yamamoto, Nobuyuki
SCIENTIFIC REPORTS, 2023, 13 (01)
[37] Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
Caldeira Marinho Matos, Joao Nunes
Sousa, Sofia Rodrigues
Figueiredo, Ana Maria
Pego, Alice
Barata, Fernando
EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[38] Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
Daichi Fujimoto
Satoru Miura
Keisuke Tomii
Hiromitsu Sumikawa
Kenichi Yoshimura
Kazushige Wakuda
Yuko Oya
Toshihide Yokoyama
Takashi Kijima
Tetsuhiko Asao
Motohiro Tamiya
Atsushi Nakamura
Hiroshige Yoshioka
Takaaki Tokito
Shuji Murakami
Akihiro Tamiya
Hiroshi Yokouchi
Satoshi Watanabe
Ou Yamaguchi
Ryotaro Morinaga
Takayuki Jodai
Kentaro Ito
Yoshimasa Shiraishi
Yoshihito Kogure
Ryota Shibaki
Nobuyuki Yamamoto
Scientific Reports, 13
[39] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
Zeng, Xiaohui
Wan, Xiaomin
Peng, Liubao
Peng, Ye
Ma, Fang
Liu, Qiao
Tan, Chongqing
BMJ OPEN, 2019, 9 (12): : e031019
[40] Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
Oakley, Brandi
Moon, Justin
Connolly, Mary
Burkard, Mark E.
Suga, J. Marie
Thomas, Sachdev
Bulen, Benjamin J.
Lamb, Laura E.
Khazanov, Nickolay A.
Hovelson, Dan
Vakil, Hana
Dusenbery, Anna
Mowers, Jonathan
Kwiatkowski, Kat
Johnson, D. Bryan
Rhodes, Daniel R.
Tomlins, Scott A.
Safa, Malek
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E47 - E47

← 1 2 3 4 5 →